Rocket One (RKTO) Net Cash Flow Growth (1y) (2019 - 2026)
Powered by 
Analysis
Rocket One (RKTO) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 349.49% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -55.11% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 172.72% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 53.21% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 47.11% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | -100.75% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,371.48% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Rocket One | 13.86 Mn | 5.97 Mn | - | 266.72% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 266.72% |
| Mar 31, 2026 | -151.46% |
| Dec 31, 2025 | -65.44% |
| Sep 30, 2025 | 47.07% |
| Jun 30, 2025 | -44.92% |
| Mar 31, 2025 | 348.20% |
| Dec 31, 2024 | 68.51% |
| Sep 30, 2024 | -312.45% |
| Jun 30, 2024 | -9.80% |
| Mar 31, 2024 | -126.03% |
| Dec 31, 2023 | -22.53% |
| Sep 30, 2023 | 132.34% |
| Jun 30, 2023 | -39.61% |
| Mar 31, 2023 | 406.36% |
| Dec 31, 2022 | 36.05% |
| Sep 30, 2022 | 29.67% |
| Jun 30, 2022 | 69.68% |
| Mar 31, 2022 | -112.97% |
| Dec 31, 2021 | -165.02% |
| Sep 30, 2021 | -310.43% |